Standex (SXI) Q4 2026 Earnings Call Transcript

Standex International (SXI) reported Q4 net sales of $228.3M (+2.8% YoY; +7.7% organically) and a record adjusted EPS of $2.45 (+7.4% YoY), alongside record Q4 free cash flow of $35.0M ($24.9M prior year). Electronics and fast-growth demand drove momentum (electronics revenue $129.1M, +12.9% organically; book-to-bill 1.27; total book-to-bill 1.18), while Aerospace & Defense grew 18.4% organically and improved margin by +410 bps to 22.5% (Edge ERP-related transitory margin drag). Management guided FY2027 sales growth to mid- to high single digits with continued margin expansion, targeted FY2028 sales >$1.1B and adjusted operating margin >23%, cut net leverage to 1.8x (from 2.6x), and raised its dividend to $0.34/share for the 248th consecutive quarter.

Analysis

The market is likely to reward the proof-of-execution more than the headline growth: SXI is transitioning from a cyclical components story into a capacity-constrained secular compounder, and the key implication is that backlog quality matters more than current revenue. The strongest second-order signal is the combination of >1.0 book-to-bill, low leverage, and FCF conversion, which gives management room to self-fund capacity without balance-sheet stress; that usually supports multiple expansion if the next 2-3 quarters show orderly conversion rather than margin erosion.

Winners are SXI’s grid and defense exposure, plus niche automation/electrification suppliers that ride the same capex wave. The losers are slower-moving incumbent industrials that rely on generic volume growth rather than product specificity; however, the real competitive risk is not named peers, it is execution slack inside SXI itself. If the ERP-related drag in Edge persists into the next two quarters or the new capacity ramps more slowly than orders, the stock can re-rate from "quality growth" back to "capex story," which is a lower multiple regime.

The contrarian read is that consensus may be underestimating how much of the FY27-FY28 upside is already gated by capacity, not demand. That means the near-term setup is not about chasing the biggest revenue beat; it is about watching whether management can translate the order base into shipments while keeping incremental margins positive. Falsifiers are simple: if organic growth slips below the guided high-single-digit range, if operating margin fails to expand despite higher sales, or if book-to-bill falls back toward 1.0, the thesis weakens quickly.

Key Decisions for Investors

• Buy SXI on any post-print weakness and hold 3-6 months for the Q1/Q2 FY27 conversion story; the setup is attractive because the balance sheet can absorb capex while backlog should support revenue. Falsifier: two consecutive quarters of organic growth below the guided range or no margin expansion.
• For beta-neutral exposure, pair long SXI / short XLI for the next 1-3 quarters to isolate company-specific execution and secular grid/defense exposure from generic industrial beta. This should work if SXI keeps >1.1 book-to-bill while XLI remains tied to macro-driven industrial softness.
• If you want a cleaner relative-value trade, long SXI / short a slower-growth electrical-industrials proxy such as ETN over 6-12 months, betting SXI’s smaller base and capacity expansion create faster incremental growth. Exit if SXI’s order-to-sales conversion lags and the market stops rewarding backlog.
• Treat SXI as a watchlist candidate for a 6-18 month structural long, not an immediate options trade: the 800V DC and grid expansion optionality is real but too early for clean option monetization. Reassess after the next two quarters of capex deployment and margin data.
• Monitor the next earnings call for evidence that grid revenue is exiting the 'capacity bottleneck' phase; if management raises the FY27 sales run-rate again without margin damage, add on confirmation rather than anticipation.